Yüklüyor......
Toxicities of Chimeric Antigen Receptor T Cell Therapy in Multiple Myeloma: An Overview of Experience From Clinical Trials, Pathophysiology, and Management Strategies
In the last few years, monoclonal antibodies (mAbs) such as elotuzumab and daratutumab have brought the treatment of multiple myeloma (MM) into the new era of immunotherapy. More recently, chimeric antigen receptor (CAR) modified T cell, a novel cellular immunotherapy, has been developed for treatme...
Kaydedildi:
| Yayımlandı: | Front Immunol |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Frontiers Media S.A.
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7793717/ https://ncbi.nlm.nih.gov/pubmed/33424871 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2020.620312 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|